TaurineTauAgeNCT06613542
Effects Of Daily Taurine Intake For 6 Months On Biological Age and Body Metabolism Indicators As Well As Physical Fitness In 55-75-year-old Women And Men
A study testing 4g of taurine daily in people with Taurine and Aging, Biological, run by Technical University of Munich at 1 site in Germany.
Trial summary
The goal of this clinical trial is to investigate the effect of taking 4 grams of taurine by older adults on aging processes over a period of 6 months. It will also check for effects of taurine on participant's physical fitness, metabolic and cognitive functions. Read more about this study
- Who is it for?
- Ages 55 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Taurine, Aging, Biological, Physical Activity
- What is being tested?
- 4g of taurine daily
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 1 siteGermany
- Study dates
- 25 Sep 2024to 13 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- women or men
- Age 55 - 75
- BMI 22 - 30 kg/m²
- written consent
Who cannot join
- Acute or chronic inflammation (e.g. flu infection)
- Severe chronic illness (e.g., Type 1 or Type 2 diabetes mellitus, COPD, renal insufficiency)
- Myocardial infarction or stroke in the previous 6 months
- Psychiatric disorder, including depression or dementia
- Weight change of ≥ 5 kg in the last 6 months
Trial locations and contacts
1 site in 1 country.
Germany1 site
Institute for Nutritional Medicine of Technical University of Munich
Munich, 80992
About this study
Official title: Effect Of Daily Taurine Supplementation For 6 Months On Biological Age and Metabolic Biomarkers As Well As Physical Fitness In 55-75-year-old Women And Men: A Randomized Controlled Intervention Study
The goal of this clinical trial is to investigate the effect of taking 4 grams of taurine by older adults on aging processes over a period of 6 months. It will also check for effects of taurine on participant's physical fitness, metabolic and cognitive functions. The main question it aims to answer is:
- Does a supplementation with 4 g of taurine daily over a period of 6 months slow down biological aging in humans? Researchers will compare supplementation with taurine to a placebo (a look-alike substance that contains no drug) to reliably determine whether taurine has an effect.
Read more
Participants will:
- Take 4g of taurine or a placebo every day for 6 months
- Visit the study site 4 times for checkups and tests: for a screening visit, at the beginning of the intervention, after 8 and 24 weeks
Read the detailed description
Measurements performed during study visits:
- Biological age estimate via proteome analysis
- Organ age estimates (proteomics)
- DNA methylation
- Inflammatory biomarkers (CRP, cytokines)
- Metabolic variables: fasting blood glucose, insulin, HOMA-IR, HbA1c, lipids, BMI
- Physical fitness (hand grip strength, leg extensor strength, PWC130)
- Resting energy expenditure
- Cognitive function via questionnaire
- Quality of life
- Heart rate variability
- Physical activity, nutrition
- Conditions
- Taurine, Aging, Biological, Physical Activity, Metabolic Health, Anti-Aging, Longevity
- Being tested
- 4g of taurine daily, Placebo
- Keywords
- taurine, biological aging, metabolic health, anti-aging, epigenetic clock, aging, physical activity, cognition, Cellular Senescence, hallmarks of aging, humans, Dietary Supplements, longevity, Taurine Deficiency, Taurine Level, aging metabolism, longevity physiology, drug effects, DNA-methylation, aging ptoeomics
- Medical subject headings
- Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
4g of taurine dailyDietary supplement
Intervention group (4g of taurine/day): 2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months
PlaceboDietary supplement
Controll group (4g of placebo/day): 2g of placebo (4 capsules, 500mg each) in the morning and 2g of placebo (4 capsules, 500mg each) in the evening for 6 months
| Study group | Role | What they receive |
|---|---|---|
| 4g of taurine daily | Active comparator | Intervention group (4g of taurine/day):
2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months Receives: Dietary Supplement: 4g of taurine daily |
| Placebo | Placebo comparator | Not described Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Biological Age At 6 Months (Proteome Analysis)
The primary objective of the study is to answer the following research question:
Does a 6-month supplementation with 4g of taurine daily slow down biological aging in humans?
Biological age will be determined using a plasma proteome analysis and established machine learning models based on plasma and urine samples. This will also include an analysis of organ-specific aging.
Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline in Biological Age At 6 Months (DNA Methylation)
The primary objective of the study is to answer the following research question:
Does a 6-month supplementation with 4g of taurine daily slow down biological aging in humans?
Biological age will be estimated by assessing DNA methylation patterns (epigenetic clock) from plasma, urine, and oral mucosa samples.
Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Secondary outcomes (12)
Change From Baseline In Cognitive Functions at 6 Months
Does a 6-month supplementation with 4 g of taurine daily influence parameters of mental health?
Methods of measurement: MoCA (Montreal Cognitive Assessment)
Measured: pre-intervention (at time point 0) and post-intervention (after 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?
Measurement: fasting blood glucose in mg/dL
Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?
Measurement: Body-Mass-Index determined by participants weight in kilograms divided by height in metres squared.
Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?
Measurement: blood pressure in mmHg
Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?
Measurement: total cholesterol in mg/dl
Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?
Measurement: LDL-cholesterol in mg/dL
Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?
Measurement: HDL-cholesterol in mg/dL
Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?
Measurement: C-reactive protein in mg/l
Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?
Measurement: fasting insulin in pmol/l
Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Handgrip Strength (kg) at 6 Months
Measurement of handgrip strength in kilograms and Newtons in the dominant hand using Jamar Hydraulic Hand Dynamometer.
Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Physical Working Capacity (PWC130) At 6 Months
Measurement of heart rate (bpm) on the Corvial ergometer while increasing power manually by 25 W every 2 minutes. The endpoint is the power in Watts at the stage where heart rate of 130bpm is reached.
Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Isometric Leg Extensor Strength For Each Leg At 6 Months
Measurement of leg extensor strength using a force transducer connected to the back of a chair and an ankle loop, as well as force recording software. The maximum force (N) will be multiplied with the distance from knee joint to the middle of the loop (in metres) to calculate the torque in Newton-metres (Nm) for each leg.
Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2024
- Study start25 Sep 2024
- Primary completion13 Nov 2025
- Study completion13 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for TaurineStudies of the same condition, open and under way.
- More trials run by Technical University of MunichThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Technical University of Munich
- Sponsor type
- University, hospital or other
- Collaborators
- Stanford University, Rutgers University, Universitaet Innsbruck, LMU Klinikum
- Responsible party
- Principal investigator, Karolina Alicja Starzynska, Technical University of Munich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06613542
- Sponsor's protocol ID
- 2024-253-S-CB
- Acronym
- TauAge
- Status last verified
- Nov 2025
- First submitted
- 17 Sep 2024
- Last updated
- 21 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: IPD will not be shared because of data privacy and confidentiality.
Publications
Oh HS, Rutledge J, Nachun D, Palovics R, Abiose O, Moran-Losada P, Channappa D, Urey DY, Kim K, Sung YJ, Wang L, Timsina J, Western D, Liu M, Kohlfeld P, Budde J, Wilson EN, Guen Y, Maurer TM, Haney M, Yang AC, He Z, Greicius MD, Andreasson KI, Sathyan S, Weiss EF, Milman S, Barzilai N, Cruchaga C, Wagner AD, Mormino E, Lehallier B, Henderson VW, Longo FM, Montgomery SB, Wyss-Coray T. Organ aging signatures in the plasma proteome track health and disease. Nature. 2023 Dec;624(7990):164-172. doi: 10.1038/s41586-023-06802-1. Epub 2023 Dec 6.
PubMed 38057571Singh P, Gollapalli K, Mangiola S, Schranner D, Yusuf MA, Chamoli M, Shi SL, Lopes Bastos B, Nair T, Riermeier A, Vayndorf EM, Wu JZ, Nilakhe A, Nguyen CQ, Muir M, Kiflezghi MG, Foulger A, Junker A, Devine J, Sharan K, Chinta SJ, Rajput S, Rane A, Baumert P, Schonfelder M, Iavarone F, di Lorenzo G, Kumari S, Gupta A, Sarkar R, Khyriem C, Chawla AS, Sharma A, Sarper N, Chattopadhyay N, Biswal BK, Settembre C, Nagarajan P, Targoff KL, Picard M, Gupta S, Velagapudi V, Papenfuss AT, Kaya A, Ferreira MG, Kennedy BK, Andersen JK, Lithgow GJ, Ali AM, Mukhopadhyay A, Palotie A, Kastenmuller G, Kaeberlein M, Wackerhage H, Pal B, Yadav VK. Taurine deficiency as a driver of aging. Science. 2023 Jun 9;380(6649):eabn9257. doi: 10.1126/science.abn9257. Epub 2023 Jun 9.
PubMed 37289866
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect Of Daily Taurine Supplementation For 6 Months On Biological Age and Metabolic Biomarkers As Well As Physical Fitness In 55-75-year-old Women And Men: A Randomized Controlled Intervention Study
- ClinicalTrials.gov ID
- NCT06613542
- Acronym / sponsor ID
- TauAge / 2024-253-S-CB
- Conditions
- Taurine, Aging, Biological, Physical Activity, Metabolic Health, Anti-Aging, Longevity
- Keywords
- taurine, biological aging, metabolic health, anti-aging, epigenetic clock, aging, physical activity, cognition
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Technical University of MunichUniversity, hospital or other
- Collaborators
- Stanford University, Rutgers University, Universitaet Innsbruck, LMU Klinikum
- Study start
- 25 Sep 2024 (actual)
- Primary completion
- 13 Nov 2025 (actual)
- Study completion
- 13 Nov 2025 (actual)
- First posted
- 26 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to investigate the effect of taking 4 grams of taurine by older adults on aging processes over a period of 6 months. It will also check for effects of taurine on participant's physical fitness, metabolic and cognitive functions. The main question it aims to answer is:
- Does a supplementation with 4 g of taurine daily over a period of 6 months slow down biological aging in humans? Researchers will compare supplementation with taurine to a placebo (a look-alike substance that contains no drug) to reliably determine whether taurine has an effect.
Participants will:
- Take 4g of taurine or a placebo every day for 6 months
- Visit the study site 4 times for checkups and tests: for a screening visit, at the beginning of the intervention, after 8 and 24 weeks
Detailed description
Measurements performed during study visits:
- Biological age estimate via proteome analysis
- Organ age estimates (proteomics)
- DNA methylation
- Inflammatory biomarkers (CRP, cytokines)
- Metabolic variables: fasting blood glucose, insulin, HOMA-IR, HbA1c, lipids, BMI
- Physical fitness (hand grip strength, leg extensor strength, PWC130)
- Resting energy expenditure
- Cognitive function via questionnaire
- Quality of life
- Heart rate variability
- Physical activity, nutrition
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 4g of taurine daily | Active comparator | Dietary Supplement: 4g of taurine dailyIntervention group (4g of taurine/day): 2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months |
| Placebo | Placebo comparator | Dietary Supplement: Placebo |
Who may qualify
- Ages
- 55 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- women or men
- Age 55 - 75
- BMI 22 - 30 kg/m²
- written consent
Key exclusion criteria (5 listed)
- Acute or chronic inflammation (e.g. flu infection)
- Severe chronic illness (e.g., Type 1 or Type 2 diabetes mellitus, COPD, renal insufficiency)
- Myocardial infarction or stroke in the previous 6 months
- Psychiatric disorder, including depression or dementia
- Weight change of ≥ 5 kg in the last 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 4g of taurine dailyIntervention group (4g of taurine/day): 2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months | Dietary supplement | 4g of taurine daily |
| PlaceboControll group (4g of placebo/day): 2g of placebo (4 capsules, 500mg each) in the morning and 2g of placebo (4 capsules, 500mg each) in the evening for 6 months | Dietary supplement | Placebo |
Primary outcome
Change From Baseline in Biological Age At 6 Months (Proteome Analysis)
Time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
The primary objective of the study is to answer the following research question: Does a 6-month supplementation with 4g of taurine daily slow down biological aging in humans? Biological age will be determined using a plasma proteome analysis and established machine learning models based on plasma and urine samples. This will also include an analysis of organ-specific aging.
Change From Baseline in Biological Age At 6 Months (DNA Methylation)
Time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
The primary objective of the study is to answer the following research question: Does a 6-month supplementation with 4g of taurine daily slow down biological aging in humans? Biological age will be estimated by assessing DNA methylation patterns (epigenetic clock) from plasma, urine, and oral mucosa samples.
12 secondary outcomes
Change From Baseline In Cognitive Functions at 6 Months
Time frame: pre-intervention (at time point 0) and post-intervention (after 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Cardiometabolic Risk Profile at 6 Months
Time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Handgrip Strength (kg) at 6 Months
Time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Physical Working Capacity (PWC130) At 6 Months
Time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Change From Baseline In Isometric Leg Extensor Strength For Each Leg At 6 Months
Time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2025.
- Background: PubMed 38057571Oh HS, Rutledge J, Nachun D, Palovics R, Abiose O, Moran-Losada P, Channappa D, Urey DY, Kim K, Sung YJ, Wang L, Timsina J, Western D, Liu M, Kohlfeld P, Budde J, Wilson EN, Guen Y, Maurer TM, Haney M, Yang AC, He Z, Greicius MD, Andreasson KI, Sathyan S, Weiss EF, Milman S, Barzilai N, Cruchaga C, Wagner AD, Mormino E, Lehallier B, Henderson VW, Longo FM, Montgomery SB, Wyss-Coray T. Organ aging signatures in the plasma proteome track health and disease. Nature. 2023 Dec;624(7990):164-172. doi: 10.1038/s41586-023-06802-1. Epub 2023 Dec 6.
- Background: PubMed 37289866Singh P, Gollapalli K, Mangiola S, Schranner D, Yusuf MA, Chamoli M, Shi SL, Lopes Bastos B, Nair T, Riermeier A, Vayndorf EM, Wu JZ, Nilakhe A, Nguyen CQ, Muir M, Kiflezghi MG, Foulger A, Junker A, Devine J, Sharan K, Chinta SJ, Rajput S, Rane A, Baumert P, Schonfelder M, Iavarone F, di Lorenzo G, Kumari S, Gupta A, Sarkar R, Khyriem C, Chawla AS, Sharma A, Sarper N, Chattopadhyay N, Biswal BK, Settembre C, Nagarajan P, Targoff KL, Picard M, Gupta S, Velagapudi V, Papenfuss AT, Kaya A, Ferreira MG, Kennedy BK, Andersen JK, Lithgow GJ, Ali AM, Mukhopadhyay A, Palotie A, Kastenmuller G, Kaeberlein M, Wackerhage H, Pal B, Yadav VK. Taurine deficiency as a driver of aging. Science. 2023 Jun 9;380(6649):eabn9257. doi: 10.1126/science.abn9257. Epub 2023 Jun 9.
- Individual participant dataSharing planned: No. IPD will not be shared because of data privacy and confidentiality.
Related trials for Taurine
Not yet recruiting
Effects of Taurine Supplementation and Morning or Evening High-intensity Exercise on Circadian Clock Genes and Inflammatory Parameters in Adult Women With Obesity
Obesity (Disorder), Inflammation
RecruitingPhase 2
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
Oral Mucositis (Ulcerative) Due to Radiation, Nasopharyngeal Carcinoma (NPC)
Recruiting
Butyrate and Taurine for Chronic Postsurgical Pain in Adult Cardiac Surgical Patients
Pain, Acute, Pain, Chronic
Not yet recruitingPhase 1/2
Taurine Supplementation in Adolescents With Post-COVID Condition
Long COVID, Post COVID-19 Condition
RecruitingPhase 2
Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes
Diabetes Mellitus, Type 2
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 4g of taurine daily in people with Taurine and Aging, Biological, run by Technical University of Munich at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Biological Age At 6 Months (Proteome Analysis) (time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06613542, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.